Response rates, survival status and adverse events of placebo in randomized control trials for hepatocellular carcinoma: A meta-analysis

doi:10.4254/wjh.v17.i8.108533

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

(55)

(62)

(0)

(8)

(1656)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Hepatol. Aug 27, 2025; 17(8): 108533
Published online Aug 27, 2025. doi: 10.4254/wjh.v17.i8.108533

Full Size Figure Download Figure

Figure 2 Forest plot of response rates in the placebo arm across the randomized controlled trials of hepatocellular carcinoma. A: Disease control rate in the placebo arm; B: Objective response rate in the placebo arm.

Citation: Chen WY, Chen Q, Wang CC, Zhang CY, Chen SK, Meng ZQ, Han P, Dong S, Chen QW. Response rates, survival status and adverse events of placebo in randomized control trials for hepatocellular carcinoma: A meta-analysis. World J Hepatol 2025; 17(8): 108533
URL: https://www.wjgnet.com/1948-5182/full/v17/i8/108533.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i8.108533

Chen WY, Chen Q, Wang CC, Zhang CY, Chen SK, Meng ZQ, Han P, Dong S, Chen QW. Response rates, survival status and adverse events of placebo in randomized control trials for hepatocellular carcinoma: A meta-analysis. World J Hepatol 2025; 17(8): 108533 [PMID: 40901596 DOI: 10.4254/wjh.v17.i8.108533]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.